VIVUS to Present at the BIO Investor Forum on October 17, 2018
October 10 2018 - 7:30AM
VIVUS, Inc. (Nasdaq: VVUS) (the “Company”), a specialty
pharmaceutical company committed to the development and
commercialization of innovative therapies focusing on treatments
for patients with serious unmet medical needs, today announced that
John Amos, Chief Executive Officer, will present at the BIO
Investor Forum on Wednesday, October 17, 2018 at 11:15am PT/2:15pm
ET in San Francisco. Mr. Amos will provide a corporate overview,
review the Company’s clinical and commercial product portfolio, and
discuss the company’s strategies for building a portfolio of cash
flow-positive assets, reducing its debt and moving toward sustained
profitability.
An audio webcast of the presentation will be
available in the events and presentations section of the Company’s
investor relations website, or by clicking here.
About VIVUS
VIVUS is a biopharmaceutical company committed
to the development and commercialization of innovative therapies
that focus on advancing treatments for patients with serious unmet
medical needs. For more information about the Company, please visit
www.vivus.com.
Forward-Looking Statements
Certain statements in this press release are
forward-looking within the meaning of the Private Securities
Litigation Reform Act of 1995. These statements may be identified
by the use of forward-looking words such as "anticipate,"
"believe," "forecast," "estimate," "expect," "intend," "likely,"
"may," "plan," "potential," "predict," "opportunity" and "should,"
among others. There are a number of factors that could cause actual
events to differ materially from those indicated by such
forward-looking statements. VIVUS does not undertake an obligation
to update or revise any forward-looking statements. Investors
should read the risk factors set forth in VIVUS' Form 10-K for the
year ended December 31, 2017 as filed on March 14, 2018, and as
amended by the Form 10-K/A filed on April 26, 2018, and periodic
reports filed with the Securities and Exchange Commission.
Contact: |
|
|
|
VIVUS, Inc. |
Lazar Partners |
Mark Oki |
David Carey |
Chief Financial Officer |
dcarey@lazarpartners.com |
oki@vivus.com |
212-687-1768 |
650-934-5200 |
|
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Mar 2024 to Apr 2024
VIVUS (NASDAQ:VVUS)
Historical Stock Chart
From Apr 2023 to Apr 2024